Cyclacel pharmaceuticals, inc. (CYCC)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-7,208

-7,830

-7,543

-7,712

-7,781

-7,288

-7,141

-6,929

-7,264

-7,470

-8,438

-9,527

-10,305

-11,791

-12,326

-12,089

-12,471

-14,342

-15,767

-17,965

-19,430

-19,387

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Change in valuation of financial instruments associated with stock purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

278

255

315

342

0

0

0

Depreciation

19

20

22

24

28

29

29

30

30

32

49

75

100

133

162

183

200

210

0

0

0

-

-

-

-

Gain on disposal of property and equipment

-

38

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Stock-based compensation

472

466

437

342

335

331

321

298

278

266

368

497

630

782

895

842

802

745

1,098

1,176

1,200

1,223

0

0

0

Changes in lease liability

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-555

-214

1,323

216

666

327

-88

374

-1,493

-1,232

-1,274

-173

516

-439

-388

-156

-1,271

-342

275

536

1,451

1,700

0

0

0

Accounts payable and other current liabilities

-2,318

-2,208

-1,869

-1,435

-133

554

-182

-436

-346

-1,540

-1,444

-1,113

-639

370

1,069

-84

-2,540

-1,466

-1,002

-713

307

666

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-10,742

-10,079

-9,812

-10,965

-12,707

-14,460

-15,452

-17,553

-18,876

-18,702

0

0

0

Net cash used in operating activities

-8,570

-9,447

-10,366

-9,078

-8,246

-6,701

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Purchase of property, plant and equipment

12

10

13

11

19

39

35

42

33

13

0

0

0

-

-

-

-

34

39

266

292

309

0

0

0

Proceeds from sale of property and equipment

-

38

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Minimum royalty payments received from termination of ALIGN license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-96

-119

-215

-311

-384

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

62

80

-51

19

75

0

0

0

Net cash provided by (used in) investing activities

-3

28

16

18

10

-39

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Proceeds from issuing common stock, net of issuance costs (Payments of issuance costs)

-

4,049

0

0

0

-

-

-

-

14,749

0

0

0

-

-

-

-

11,061

12,032

11,812

21,178

12,421

0

0

0

Payment of preferred stock dividend

201

201

201

201

201

201

201

201

201

201

201

201

200

200

201

201

201

201

200

200

200

200

0

0

0

Net cash provided by (used in) financing activities

-258

3,848

4,478

4,485

4,535

429

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by / (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

6,680

6,594

5,525

658

427

10,860

11,811

11,591

20,957

12,200

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

1

176

135

98

58

-331

-444

-483

-725

-21

-211

-418

-541

-891

-530

0

0

0

Net (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

6,233

8,996

7,390

7,996

-2,340

-4,386

-3,920

-4,699

-10,971

-12,248

-3,749

0

0

0

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplemental cash flow information:
Interest

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash received during the period for: Interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

6

0

0

0

Lease liability

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

Taxes

-

-

-

-

-

-

-

0

1,807

1,815

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

Non cash financing activities:
Accrual of preferred stock dividends

50

50

50

50

50

50

50

50

50

50

50

50

50

50

50

50

50

50

0

0

0

-

-

-

-